Compare TTSH & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTSH | NPCE |
|---|---|---|
| Founded | 1985 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.3M | 328.8M |
| IPO Year | N/A | 2021 |
| Metric | TTSH | NPCE |
|---|---|---|
| Price | $6.57 | $16.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.29 |
| AVG Volume (30 Days) | ★ 301.2K | 248.7K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,787,000.00 | $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $4.62 | $7.56 |
| 52 Week High | $7.75 | $18.98 |
| Indicator | TTSH | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 62.47 |
| Support Level | $6.35 | $16.00 |
| Resistance Level | $6.57 | $16.94 |
| Average True Range (ATR) | 0.07 | 0.80 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 94.00 | 68.23 |
Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.